Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Precision medicine in hematological oncology: development to the present day

Tariq Mughal • 25 Feb 2019
ISAL 2019
Chronic Myeloid Leukemia General Leukemia Imatinib

Tariq Mughal, MD, MB, BS, MRCS, MRCP, FRCP, of Tufts University School of Medicine, Boston, MA, gives us a comprehensive background of the devlopment of precision medicine in the field of hematological oncology. Starting with the case of imatinib in chronic myeloid leukemia (CML), he takes us through to the present day. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Tariq Mughal

4:23
Acute leukemias: the doubled-edged sword of genetic complexity
Tariq Mughal • 25 Feb 2019
2:25
The importance of genetic profiling: NGS, MRD & beyond
Tariq Mughal • 25 Feb 2019

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals